Eikon Therapeutics, Inc. (EIKN)
9.21
-1.52
(-14.17%)
USD |
NASDAQ |
Sep 10, 16:00
9.20
-0.01
(-0.11%)
After-Hours: 06:26
Eikon Therapeutics Enterprise Value : 219.35M for Sept. 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 10, 2026 | 219.35M |
| September 09, 2026 | 301.66M |
| September 08, 2026 | 300.58M |
| September 04, 2026 | 308.70M |
| September 03, 2026 | 314.11M |
| September 02, 2026 | 336.86M |
| September 01, 2026 | 309.78M |
| August 31, 2026 | 287.04M |
| August 28, 2026 | 315.20M |
| August 27, 2026 | 344.44M |
| August 26, 2026 | 369.34M |
| August 25, 2026 | 400.21M |
| August 24, 2026 | 324.94M |
| August 21, 2026 | 337.40M |
| August 20, 2026 | 302.74M |
| August 19, 2026 | 370.97M |
| August 18, 2026 | 351.48M |
| August 17, 2026 | 287.58M |
| August 14, 2026 | 318.99M |
| August 13, 2026 | 280.00M |
| August 12, 2026 | 284.87M |
| August 11, 2026 | 274.58M |
| August 10, 2026 | 247.51M |
| August 07, 2026 | 223.68M |
| August 06, 2026 | 219.35M |
| Date | Value |
|---|---|
| August 05, 2026 | 237.76M |
| August 04, 2026 | 238.30M |
| August 03, 2026 | 216.10M |
| July 31, 2026 | 219.35M |
| July 30, 2026 | 241.55M |
| July 29, 2026 | 208.52M |
| July 28, 2026 | 234.51M |
| July 27, 2026 | 255.63M |
| July 24, 2026 | 202.57M |
| July 23, 2026 | 241.55M |
| July 22, 2026 | 241.01M |
| July 21, 2026 | 257.26M |
| July 20, 2026 | 243.18M |
| July 17, 2026 | 249.68M |
| July 16, 2026 | 259.42M |
| July 15, 2026 | 253.47M |
| July 14, 2026 | 272.42M |
| July 13, 2026 | 285.96M |
| July 10, 2026 | 293.54M |
| July 09, 2026 | 328.19M |
| July 08, 2026 | 301.12M |
| July 07, 2026 | 348.77M |
| July 06, 2026 | 372.05M |
| July 02, 2026 | 399.67M |
| July 01, 2026 | 383.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.892B |
| Alnylam Pharmaceuticals, Inc. | 32.78B |
| Anika Therapeutics, Inc. | 267.75M |
| Savara, Inc. | 950.10M |
| Vericel Corp. | 1.870B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -88.41M |
| Total Expenses (Quarterly) | 88.41M |
| EPS Diluted (Quarterly) | -1.633 |
| Earnings Yield | -71.44% |
| Normalized Earnings Yield | -71.44 |